- Report
- May 2026
- 120 Pages
Global
From €5405EUR$5,950USD£4,665GBP
- Report
- November 2025
- 150 Pages
Global
From €5405EUR$5,950USD£4,665GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,520GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,520GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,520GBP
- Report
- June 2026
- 380 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 384 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 577 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 578 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 172 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 184 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 360 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 262 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- January 2026
- 194 Pages
Global
From €3220EUR$3,545USD£2,779GBP
€3578EUR$3,939USD£3,088GBP
- Report
- June 2026
- 188 Pages
Global
From €3220EUR$3,545USD£2,779GBP
€3578EUR$3,939USD£3,088GBP
- Report
- June 2026
- 182 Pages
Global
From €3220EUR$3,545USD£2,779GBP
€3578EUR$3,939USD£3,088GBP
- Report
- January 2026
- 192 Pages
Global
From €3220EUR$3,545USD£2,779GBP
€3578EUR$3,939USD£3,088GBP
- Report
- January 2026
- 184 Pages
Global
From €3220EUR$3,545USD£2,779GBP
€3578EUR$3,939USD£3,088GBP
- Report
- November 2025
- 189 Pages
Global
From €3220EUR$3,545USD£2,779GBP
€3578EUR$3,939USD£3,088GBP
- Report
- August 2025
- 199 Pages
Global
From €3220EUR$3,545USD£2,779GBP
€3578EUR$3,939USD£3,088GBP

Continuous bioprocessing is a biotechnology-based approach to the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. It involves the use of continuous manufacturing techniques, such as continuous cell culture, continuous chromatography, and continuous purification, to produce biopharmaceuticals in a more efficient and cost-effective manner than traditional batch-based processes. This approach also allows for greater control over the production process, resulting in higher quality products.
Continuous bioprocessing has become increasingly popular in recent years, as it offers a number of advantages over traditional batch-based processes. These include improved process control, increased product yield, reduced production costs, and shorter production times.
Some companies in the continuous bioprocessing market include Merck KGaA, Novartis, Pfizer, Sanofi, and Lonza. Show Less Read more